Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma.
This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2.
The study demonstrates that FGFR2b is the predominant FGFR2 isoform in intrahepatic cholangiocarcinoma (iCCA) and is highly enriched in tumor tissue, making it a promising therapeutic target for future antibody‑drug conjugate or other biologic treatments.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
- Scientists build cell line atlas of deadly cancers of the bile ducts and gallbladder
- Cholangiocarcinoma Workup: Laboratory Studies, Imaging Studies, Procedures
- New EASL Clinical Practice Guidelines on extrahepatic cholangiocarcinoma
- An open‑label study of pemigatinib in cholangiocarcinoma: final results from FIGHT‑202